Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 08, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative...
Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine
April 06, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Achieved freedom from migraine pain in 33% of AXS-07 patients versus 16% for placebo at 2 hours (co-primary endpoint, p=0.002) Prevented progression of migraine pain beyond mild intensity in 74% of...
Migraine Drugs Market To Reach USD 3.51 Billion By 2026 | Reports And Data
February 24, 2020 11:30 ET
|
Reports and Data
New York, Feb. 24, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global Migraine Drugs market was valued at USD 1.29 billion in 2018 and is expected to reach...
Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine
February 20, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response
December 30, 2019 06:15 ET
|
Axsome Therapeutics, Inc.
Demonstrated statistical significance on regulatory co-primary endpoints of pain freedom (p<0.001) and freedom from most bothersome symptom (p=0.002) at 2 hours, compared to placebo Demonstrated...
Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting
December 12, 2019 07:00 ET
|
Trevena Inc.
Safety, tolerability, and PK profile support potential utility as a novel acute migraine treatment option CHESTERBROOK, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a...
Neurodiagnostics Market To Reach USD 25.14 Billion By 2026 | Reports And Data
November 26, 2019 10:24 ET
|
Reports and Data
New york, Nov. 26, 2019 (GLOBE NEWSWIRE) -- High prevalence of neurological disorders, adoption of novel diagnostic technology, product launches, increasing strategic developments such as...
Neurodiagnostics Market To Reach USD 25.14 Billion By 2026 | Reports And Data
November 26, 2019 10:24 ET
|
Reports and Data
New york, Nov. 26, 2019 (GLOBE NEWSWIRE) -- High prevalence of neurological disorders, adoption of novel diagnostic technology, product launches, increasing strategic developments such as...
Axsome Therapeutics to Host Investor R&D Call with Key Opinion Leaders Focusing on AXS-07 and the Unmet Needs in the Acute Treatment of Migraine
November 21, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Company to host conference call on Monday, November 25 at 9:00 AM Eastern NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
OWP Pharmaceuticals Announces IND Approval and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Topiramate for the Treatment of Epilepsy and Migraine
November 20, 2019 08:00 ET
|
OWP Pharmaceuticals
NAPERVILLE, Ill., Nov. 20, 2019 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...